As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...